Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Surg Oncol Clin N Am. 2015 Jan 24;24(2):347–358. doi: 10.1016/j.soc.2014.12.011

Figure 1.

Figure 1

Frequency of somatic mutations that were previously identified in the work presented in the Hodis et al. Cell 2012 and applied in the publicly available cohort of cutaneous melanoma samples that has been collected as part of the Cancer Genome Atlas Project. Only 257 out of the so far (August 17, 2014) analyzed 375 samples that bear mutations (green dots) in any of these genes are shown. NF1, HRAS, and KRAS are also presented to emphasize the 4 emerging subgroups on the basis of BRAF, RAS, NF1 mutations, versus no mutation (triple-wild type group). Mutations highlighted with red border signify non-canonical mutations. Most genes, highlighted in red, are components of the BRAF/MEK/ERK, or PI3K/Akt signaling (see Figure 3 for further details). Analysis was performed using the cBioportal for Cancer Genomics (www.cbioportal.org) in compliance with early publication of results from the website, ad per Cerami et al. Cancer Discov 2012 and Gao et al. Sci Signal. 2013.